Synaptogenix | Press Release

261

archive,category,category-press-release,category-261,wp-theme-stockholm,ajax_fade,page_not_loaded,,select-theme-ver-4.4,wpb-js-composer js-comp-ver-5.4.7,vc_responsive

February 7, 2018 In Press Release

Neurotrope to Present at BIO CEO & Investor Conference

...

January 25, 2018 In Press Release

Neurotrope to Present at NobleCon 14th Annual Institutional Investor Conference

...

January 5, 2018 In Press Release

Neurotrope’s Bryostatin Improves Cognition in Patients with Advanced Alzheimer’s Disease Based on Further Analysis of Phase 2 Clinical Trial Data

...

December 19, 2017 In Press Release

Neurotrope Appoints Charles S. Ryan as Chief Executive Officer

...

December 19, 2017 In Press Release

Neurotrope to Present Additional Findings from Bryostatin Phase 2 Trial in Advanced Alzheimer’s Disease

...

August 9, 2017 In Press Release

Neurotrope Provides Business Update and Reports Second Quarter 2017 Financial Results

...

July 19, 2017 In Press Release

Neurotrope Presents Phase 2 Data Assessing Bryostatin-1 in Moderate-to-Severe Alzheimer’s Patients at AAIC 2017

...

June 29, 2017 In Press Release

Neurotrope to Present Bryostatin Phase 2 Data in an Oral Presentation at AAIC 2017 Meeting

...

May 1, 2017 In Press Release

NEUROTROPE Announces Positive Top-Line Results From Phase 2 Study of Bryostatin-1 for Moderate to Severe Alzheimer’s Disease

...

March 27, 2017 In Press Release

Neurotrope Inc. Announces Approval for Listing on the NASDAQ Capital Market

...

March 24, 2017 In Press Release

Neurotrope’s President and Chief Scientific Officer to Present Keynote Address at Sachs Associates’ 2nd Annual Neuroscience Biopartnering & Investment Forum

...

March 16, 2017 In Press Release

Neurotrope BioScience to Present at the Oppenheimer 27th Annual Healthcare Conference

...

February 28, 2017 In Press Release

Neurotrope Bioscience Concludes Patient Dosing and Monitoring in its 148 Patient Phase 2 Clinical Trial of Moderate to Severe Alzheimer’s Dementia

...

February 7, 2017 In Press Release

Neurotrope Bioscience to Present at the 19th Annual BIO CEO & Investor Conference 2017

...

January 30, 2017 In Press Release

Neurotrope Completes Licensing Agreement for Accelerated Synthesis of Alzheimer’s Drug Bryostatin-1

...

January 27, 2017 In Press Release

Neurotrope Bioscience to Present at the Noble Financial Capital Markets’ 13th Annual Investor Conference

...

January 12, 2017 In Press Release

Neurotrope Announces Reverse Split of Common Stock in Preparation for NASDAQ Uplisting

...

January 5, 2017 In Press Release

NEUROTROPE TO PRESENT AT TWO UPCOMING INVESTOR CONFERENCES

...

November 23, 2016 In Press Release

Neurotrope Issues Statement On Eli Lilly’s Solanezumab

...

November 22, 2016 In Press Release

Neurotrope Completes Enrollment In Its Randomized, Double-blinded, Placebo-controlled Phase 2 Clinical Trial of Bryostatin In Patients With Moderate To Severe Alzheimers Disease

...

November 18, 2016 In Press Release

Neurotrope Announces Private Placement of $20 Million

...

September 28, 2016 In Press Release

Dr. Daniel Alkon Appointed President of Neurotrope, Inc.

...

September 6, 2016 In Press Release

Susanne Wilke, PhD Appointed Chief Executive Officer of Neurotrope, Inc.

...

August 15, 2016 In Press Release

Neurotrope Submits an Amended Protocol to the U.S. Food and Drug Administration for its Phase 2b Clinical Trial of its Lead Drug Candidate, Bryostatin-1, for the Treatment of Advanced Alzheimer’s Disease

...

August 5, 2016 In Press Release

NEUROTROPE ANNOUNCES CHANGES TO THE BOARD OF DIRECTORS AND MANAGMENT

...

June 13, 2016 In Press Release

Neurotrope’s Chief Scientific Officer Dr. Daniel Alkon Presents at the Gordon Conference: Drugs That Target Common Mechanisms for Synaptic Restoration in Mental Retardation and Alzheimer’s Disease

...

May 18, 2016 In Press Release

Neurotrope Enters Into Research Collaboration With the International Rett Syndrome Foundation / Rettsyndrome.org

...

March 7, 2016 In Press Release

Neurotrope Announces Publication Demonstrating Synaptic Regeneration with the PKC epsilon Activator Bryostatin, in a Fragile X Disease Late Brain Development Model

...

February 11, 2016 In Press Release

Neurotrope Doses First Patients in Phase 2b Study of Bryostatin for Treatment of Severe Alzheimer’s Disease

...

February 11, 2016 In Press Release

Neurotrope Doses First Patients in Phase 2b Study of Bryostatin for Treatment of Severe Alzheimer’s Disease

...

February 3, 2016 In Press Release

Neurotrope Holds Investigators Meeting for U.S. Phase 2b Trial of Bryostatin-1 for Treatment of Alzheimer’s Disease

...

November 16, 2015 In Press Release

Neurotrope, Inc. Announces $15.3 million Private Placement

...

July 20, 2015 In Press Release

Neurotrope to Showcase Bryostatin as a Potential Treatment for Alzheimer’s Disease at the 2015 Alzheimer’s Association International Conference

...

June 24, 2015 In Press Release

Neurotrope to Conduct Study on Niemann-Pick Type C, a Devastating Rare Pediatric Disease

...

April 16, 2015 In Press Release

Neurotrope Receives Research Grant from the FRAXA Research Foundation to Fund Pre-Clinical Fragile X Syndrome Behavioral Studies

...

April 6, 2015 In Press Release

Neurotrope Selects Worldwide Clinical Trials to Commence Services for Phase 2B Trial of Bryostatin for the Treatment of Alzheimer’s Disease

...

February 24, 2015 In Press Release

Neurotrope Announces Positive Top-Line Results From Its Phase 2a Study of Bryostatin-1 in Alzheimer’s Disease

...

February 24, 2015 In Press Release

Neurotrope Announces Positive Top-Line Results From Its Phase 2a Study of Bryostatin-1 in Alzheimer’s Disease

...

January 13, 2015 In Press Release

Neurotrope Forms Clinical Advisory Board to Support Alzheimer’s Disease Program

...

January 6, 2015 In Press Release

Neurotrope to Present at the Biotech Showcase 2015 Conference

...

August 18, 2014 In Press Release

Neurotrope’s Approach to Treating Alzheimer’s Disease Through Its Product Bryostatin-1, an Activator of Protein Kinase C Epsilon (PKCe), Supported by Blanchette Rockefeller Neurosciences Institute (BRNI) Publication, Identifying PKCe as a Biomarker of Alzheimer’s

...

July 29, 2014 In Press Release

Neurotrope Initiates Phase 2a Study of Bryostatin for the Treatment of Alzheimer’s Disease – Doses First Patients

...

July 22, 2014 In Press Release

Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C

...

July 18, 2014 In Press Release

Neurotrope Board of Directors Appoints Chairmen Ramat and Freiman as Interim Co-CEOs

...

July 15, 2014 In Press Release

Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C

...

June 19, 2014 In Press Release

Neurotrope Appoints Charles S. Ramat and Paul Freiman as Co-Chairman of the Board

...

June 4, 2014 In Press Release

Neurotrope Appoints Neuroscientist Sam Kongsamut as Executive Director, Pharmacology

...

May 28, 2014 In Press Release

Neurotrope Announces Publication of Positive Human Cell Culture and Mouse Model Data of Bryostatin 1

...

May 20, 2014 In Press Release

Neurotrope, Inc. Collaborating with Dr. Paul Wender and Stanford University on Bryostatin Analogues

...

April 15, 2014 In Press Release

Neurotrope, Inc. Files Provisional Patent Application on the Use of Bryostatin for the Treatment of Niemann-Pick Disease Type C

...